Top

Published in:

01-03-2012 | Original Article

Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer

Authors: Shunichi Tsujitani, Hiroaki Saito, Toshiro Wakatsuki, Masahide Ikeguchi, Ken Shirabe, Masaru Morita, Yoshihiro Kakeji, Tokujiro Yano, Yoshihiko Maehara

Published in: Surgery Today | Issue 3/2012

Abstract

Purpose

We investigated the relationship between the p53-dependent apoptotic pathway and the survival of patients with gastric cancer, retrospectively, to elucidate new biomarkers of uracil/tegafur (UFT) chemotherapy.

Methods

We examined the expression of p53, p21, Bax, and myeloid cell leukemia 1 (Mcl-1) proteins immunohistochemically in 105 patients who underwent curative gastrectomy for gastric cancer invading the serosa. Postoperative oral UFT was prescribed for 1 year. Kaplan–Meier survival curves were compared with the two-sided log-rank test.

Results

Positive staining for p53, p21, Bax, and Mcl-1 proteins was found in 63.8, 52.4, 39.0, and 72.4% of the subjects, respectively. Survival time did not differ significantly between the patients with and those without p53, p21, and Bax expression. However, patients with Mcl-1(−) tumors survived longer than those with Mcl-1(+) tumors. Postoperative UFT treatment did not improve survival; however, adjuvant UFT significantly prolonged the survival of patients with p53(−), p21(−), Bax(+), or Mcl-1(+) tumors, but not of patients with p53(+), p21(+), Bax(−), or Mcl-1(−) tumors.

Conclusions

The efficacy of adjuvant chemotherapy for gastric cancer may be affected by the status of apoptosis-related proteins such as p53, p21, Bax, and Mcl-1. However, because susceptibility to apoptosis did not explain the sensitivity of chemotherapeutic agents, further investigation of the mutual interaction between apoptosis-related proteins is required.

Noguchi Y, Imada T, Matsumoto A, Goit DG, Brennan MF. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer. 1989;64:2053–62.PubMedCrossRef

Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70:1030–7.PubMedCrossRef

Otani S, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Hamazoe R, et al. Long-term survival of 5 years following initial surgery for gastric cancer and simultaneous disseminated peritoneal metastasis; report of a case. Surg Today. 1995;25:959–61.PubMedCrossRef

Kaibara N, Nishidoi H, Kimura O, Makino M, Sumi K, Koga S. Analysis of results of surgical treatment of gastric cancer. Retrospective study of 1,215 curatively resected cases. Dig Surg. 1988;5:124–7.CrossRef

Maehara Y, Okuyama T, Oshiro T, Baba H, Adachi Y, Sugimachi K. Analysis of 390 patients surviving 10 years or longer after curative resection for gastric cancer. Oncology. 1994;51:366–71.PubMedCrossRef

Deng J, Liang H, Wang D, Sun D, Pan Y, Liu Y. Investigations of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41:210–5.PubMedCrossRef

El-Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169–74.PubMed

Sheikh MS, Rochefort H, Garcia M. Overexpression of p21waf1/cip1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 1995;11:1899–905.PubMed

Zhan Q, Bae I, Kastan MB, Fornace AF Jr. The p53-dependent gamma-ray response of GADD45. Cancer Res. 1994;54:2755–60.PubMed

10.

Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O’Connor PM, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 1994;9:3743–51.PubMed

11.

Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;8:531–9.PubMed

12.

Lane D, Benchimol S. p53: oncogene or anti-oncogene. Genes Dev. 1990;4:1–8.PubMedCrossRef

13.

Starzynska T, Blomley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer. 1992;66:558–62.PubMedCrossRef

14.

Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992;50:859–62.PubMedCrossRef

15.

Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinoma. Am J Surg Pathol. 1994;18:1247–53.PubMedCrossRef

16.

Loewe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–67.CrossRef

17.

Yamashita K, Sakuramoto S, Watababe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today. 2011;41:24–38.PubMedCrossRef

18.

Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391–5.PubMed

19.

Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford TD, et al. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res. 1995;55:2404–9.PubMed

20.

Barboule N, Mazars P, Baldin V, Vidal S, Jozan S, Martel P, et al. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer. 1995;63:611–5.PubMedCrossRef

21.

Kerr J, Wylle A, Currie A. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.PubMedCrossRef

22.

Manning FC, Patienro SR. Apoptosis: inhibitor or instigator of carcinogenesis? Cancer Invest. 1996;14:455–65.PubMedCrossRef

23.

Korsmeyer SJ. Bcl-2 initiates a new category of oncogene; regulators of cell death. Blood. 1992;80:879–86.PubMed

24.

Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614–20.PubMedCrossRef

25.

Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 1999;59(Suppl):1693s–700s.PubMed

26.

Reynold JE, Li J, Craig RW, Eastman A. BCL-2 and Mcl-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Exp Cell Res. 1996;225:430–6.CrossRef

27.

Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res. 1996;56:40–3.PubMed

28.

Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89:630–43.PubMed

29.

Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood. 1996;88:386–401.PubMed

30.

Shigemasa K, Katoh O, Shiroyama Y. Increased MCL-1expression is associated with poor prognosis in ovarian cancer. Jpn J Cancer Res. 2002;93:542–50.PubMedCrossRef

31.

Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP. Bcl-XL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 1995;55:2576–82.PubMed

32.

Baekeland M, Horm R, Neslannd JM, Trope CG, Kristensen GB. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol. 2000;18:3775–81.

33.

Rieger M, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R. Bcl-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci. 1998;155:68–75.PubMedCrossRef

34.

Erenpreisa J, Cragg MS. Mitotic death: a mechanism of survival? A review. Cancer Cell Int. 2001;1:1–7.PubMedCrossRef

35.

Kubicka S, Claas C, Staab S, Kühnel F, Zender L, Trautwein C, et al. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002;47:114–21.PubMedCrossRef

36.

Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature. 1997;358:123–5.CrossRef

37.

Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 1998;58:1793–7.PubMed

38.

Hashimoto T, Tokuchi Y, Hayashi M, Kaobayashi Y, Nishida K, Hayashi S, et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 1999;59:5572–7.PubMed

39.

Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, et al. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers. Oncogene. 1995;16:681–8.

40.

Bataille F, Rümmele P, Dietmaier W, Gaag D, Klebi F, Reichle A, et al. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. J Clin Pathol Mol Pathol. 2003;56:286–92.CrossRef

41.

Ikeguchi M, Tatebe S, Kaibara N, Ito H. Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Eur Surg Res. 1997;29:396–402.PubMedCrossRef

42.

Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res. 2000;6:4782–8.PubMed

43.

Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117–29.PubMedCrossRef

44.

Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997;79:2067–72.PubMedCrossRef

45.

Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvagoet J, Song K, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancer. Am J Pathol. 1996;148:1567–76.PubMed

46.

Krajewska M, Moss SF, Krajewski S, Holt PR, Song K, Holt PR, et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 1996;56:2422–7.PubMed

47.

Krajewska M, Fenoglio Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinoma of the stomach. Am J Pathol. 1996;149:1449–57.PubMed

48.

Maeta Y, Tsujitani S, Yamaguchi K, Tatebe S, Kondo A, Ikeguchi M, et al. Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer. 2004;7:78–84.PubMedCrossRef

49.

Puthier D, Bataille R, Amiot M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29:3945–50.PubMedCrossRef

50.

Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene. 2001;20:5799–809.PubMedCrossRef

51.

Huang HM, Huang CJ, Yen JJ. Mcl-1 is a common target stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and a PI3-K/Akt pathways. Blood. 2000;96:1764–71.PubMed

52.

Li L, Krajewski S, Reed JC, Choi YS. The apoptosis and proliferation of SAC-activated B cell by IL-10 are associated with change in Bcl-2, Bcl-xL, and Mcl-1 expression. Cell Immunol. 1997;178:33–41.PubMedCrossRef

53.

Lomo J, Blomhoff HK, Jacobcen SE, Krajewski S, Reed JC, Smeland EB. Interleukin 13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1 expression. Blood. 1997;89:4415–24.PubMed

54.

Kuo ML, Chuang SE, Lin MT, Yang SY. The involvement of PI3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Her3B cells by Interleukin-6. Oncogene. 2001;20:677–85.PubMedCrossRef

55.

Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The apoptotic gene Mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol. 1999;19:6195–206.PubMed

Title: Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer
Authors: Shunichi Tsujitani
Hiroaki Saito
Toshiro Wakatsuki
Masahide Ikeguchi
Ken Shirabe
Masaru Morita
Yoshihiro Kakeji
Tokujiro Yano
Yoshihiko Maehara
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Surgery Today / Issue 3/2012
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-011-0062-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Successful closure of an open-window thoracostomy wound by negative-pressure wound therapy: report of a case

Implications of surgical intervention in the treatment of neuroblastomas: 20-year experience of a single institution

Effectiveness of muscle coverage to manage osteomyelitis of very late onset in the irradiated chest wall

Off-the-job training for VATS employing anatomically correct lung models

Yellow nail syndrome with thoracic empyema: report of a case

Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient